Literature DB >> 27511833

Prognostic implications of 2005 Gleason grade modification. Population-based study of biochemical recurrence following radical prostatectomy.

Frederik B Thomsen1, Yasin Folkvaljon2, Klaus Brasso3, Stacy Loeb4, David Robinson5,6, Lars Egevad7, Pär Stattin5,8.   

Abstract

OBJECTIVE: To assess the impact of the 2005 modification of the Gleason classification on risk of biochemical recurrence (BCR) after radical prostatectomy (RP). PATIENTS AND METHODS: In the Prostate Cancer data Base Sweden (PCBaSe), 2,574 men assessed with the original Gleason classification and 1,890 men assessed with the modified Gleason classification, diagnosed between 2003 and 2007, underwent primary RP. Histopathology was reported according to the Gleason Grading Groups (GGG): GGG1 = Gleason score (GS) 6, GGG2 = GS 7(3 + 4), GGG3 = GS 7(4 + 3), GGG4 = GS 8 and GGG5 = GS 9-10. Cumulative incidence and multivariable Cox proportional hazards regression models were used to assess difference in BCR.
RESULTS: The cumulative incidence of BCR was lower using the modified compared to the original classification: GGG2 (16% vs. 23%), GGG3 (21% vs. 35%) and GGG4 (18% vs. 34%), respectively. Risk of BCR was lower for modified versus original classification, GGG2 Hazard ratio (HR) 0.66, (95%CI 0.49-0.88), GGG3 HR 0.57 (95%CI 0.38-0.88) and GGG4 HR 0.53 (95%CI 0.29-0.94).
CONCLUSION: Due to grade migration following the 2005 Gleason modification, outcome after RP are more favourable. Consequently, outcomes from historical studies cannot directly be applied to a contemporary setting. J. Surg. Oncol. 2016;114:664-670.
© 2016 Wiley Periodicals, Inc. © 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  Gleason classification; ISUP; biochemical recurrence; prostate cancer; radical prostatectomy

Mesh:

Substances:

Year:  2016        PMID: 27511833      PMCID: PMC5559082          DOI: 10.1002/jso.24408

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  39 in total

1.  Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging.

Authors:  D F Gleason; G T Mellinger
Journal:  J Urol       Date:  1974-01       Impact factor: 7.450

2.  Nationwide, population-based study of prostate cancer stage migration between and within clinical risk categories.

Authors:  Erin L Ohmann; Stacy Loeb; David Robinson; Anna Bill-Axelson; Anders Berglund; Pär Stattin
Journal:  Scand J Urol       Date:  2014-03-11       Impact factor: 1.612

Review 3.  Active surveillance for clinically localized prostate cancer--a systematic review.

Authors:  Frederik B Thomsen; Klaus Brasso; Laurence H Klotz; M Andreas Røder; Kasper D Berg; Peter Iversen
Journal:  J Surg Oncol       Date:  2014-03-07       Impact factor: 3.454

4.  Prostate cancer and the Will Rogers phenomenon.

Authors:  Peter C Albertsen; James A Hanley; George H Barrows; David F Penson; Pam D H Kowalczyk; M Melinda Sanders; Judith Fine
Journal:  J Natl Cancer Inst       Date:  2005-09-07       Impact factor: 13.506

5.  Comorbidity, treatment and mortality: a population based cohort study of prostate cancer in PCBaSe Sweden.

Authors:  Anders Berglund; Hans Garmo; Carol Tishelman; Lars Holmberg; Pär Stattin; Mats Lambe
Journal:  J Urol       Date:  2011-01-15       Impact factor: 7.450

6.  Evaluation of data quality in the National Prostate Cancer Register of Sweden.

Authors:  Katarina Tomic; Fredrik Sandin; Annette Wigertz; David Robinson; Mats Lambe; Pär Stattin
Journal:  Eur J Cancer       Date:  2014-11-20       Impact factor: 9.162

Review 7.  The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System.

Authors:  Jonathan I Epstein; Lars Egevad; Mahul B Amin; Brett Delahunt; John R Srigley; Peter A Humphrey
Journal:  Am J Surg Pathol       Date:  2016-02       Impact factor: 6.394

8.  Long-term outcomes among noncuratively treated men according to prostate cancer risk category in a nationwide, population-based study.

Authors:  Jennifer R Rider; Fredrik Sandin; Ove Andrén; Peter Wiklund; Jonas Hugosson; Pär Stattin
Journal:  Eur Urol       Date:  2012-08-10       Impact factor: 20.096

9.  Evaluation of the 2015 Gleason Grade Groups in a Nationwide Population-based Cohort.

Authors:  Stacy Loeb; Yasin Folkvaljon; David Robinson; Ingela Franck Lissbrant; Lars Egevad; Pär Stattin
Journal:  Eur Urol       Date:  2015-12-17       Impact factor: 20.096

10.  Cohort Profile: the National Prostate Cancer Register of Sweden and Prostate Cancer data Base Sweden 2.0.

Authors:  Mieke Van Hemelrijck; Annette Wigertz; Fredrik Sandin; Hans Garmo; Karin Hellström; Per Fransson; Anders Widmark; Mats Lambe; Jan Adolfsson; Eberhard Varenhorst; Jan-Erik Johansson; Pär Stattin
Journal:  Int J Epidemiol       Date:  2012-05-04       Impact factor: 7.196

View more
  1 in total

Review 1.  The presence of secondary circulating prostate tumour cells determines the risk of biochemical relapse for patients with low- and intermediate-risk prostate cancer who are treated only with external radiotherapy.

Authors:  Nigel P Murray; Socrates Aedo; Cynthia Fuentealba; Eduardo Reyes; Simone Minzer; Aníbal Salazar
Journal:  Ecancermedicalscience       Date:  2018-06-20
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.